Adeona Launches Phase II Clinical Trial of Trimesta

Adeona Pharmaceuticals announced the initiation of the Phase II clinical trial of Trimesta for the treatment of cognitive dysfunction in multiple sclerosis.

Adeona Pharmaceuticals, Inc. announced Thursday the initiation of the Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis.

This clinical trial is intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients at University of California, Los Angeles (UCLA) and is being conducted at by Principal Investigator, Rhonda Voskuhl, M.D., Director, UCLA Multiple Sclerosis Program, Department of Neurology. There is currently no approved therapy for the treatment of cognitive dysfunction in MS.

"We are very excited to initiate patient enrollment in this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition. Statistics show that 50-